{"id":"fosamax-plus-d","safety":{"commonSideEffects":[{"rate":"5-15","effect":"Gastrointestinal upset (nausea, dyspepsia, abdominal pain)"},{"rate":"5-10","effect":"Musculoskeletal pain"},{"rate":"3-5","effect":"Headache"},{"rate":"1-3","effect":"Esophageal irritation"},{"rate":"<1","effect":"Atypical femoral fracture (rare)"}]},"_chembl":{"chemblId":"CHEMBL870","moleculeType":"Small molecule","molecularWeight":"249.10"},"_dailymed":{"setId":"10307e7e-9a84-4aa1-8c5c-4b209cffe4d1","title":"FOSAMAX PLUS D (ALENDRONATE SODIUM AND CHOLECALCIFEROL) TABLET [ORGANON LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Alendronate works by binding to hydroxyapatite in bone and inhibiting osteoclast-mediated bone resorption, thereby increasing bone mineral density. Cholecalciferol supplementation ensures adequate vitamin D levels, which is essential for calcium absorption and bone health. Together, these components address both the primary pathology of osteoporosis and a common nutritional deficiency that impairs treatment efficacy.","oneSentence":"FOSAMAX PLUS D combines alendronate (a bisphosphonate that inhibits bone resorption) with cholecalciferol (vitamin D3) to prevent and treat osteoporosis while ensuring adequate vitamin D status.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:32:47.997Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Osteoporosis prevention and treatment in postmenopausal women"},{"name":"Osteoporosis in men"},{"name":"Glucocorticoid-induced osteoporosis"}]},"trialDetails":[{"nctId":"NCT07435051","phase":"PHASE3","title":"Prospective, Randomized, Multicenter Clinical Trial of Bisphosphonates Combined With Vancomycin for the Treatment of Cierny-Mader Type I and III Osteomyelitis","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-05-01","conditions":"Osteomyelitis (Refractory)","enrollment":280},{"nctId":"NCT07242612","phase":"NA","title":"Bone Turnover Markers and Treatment Efficacy in Postmenopausal Osteoporosis","status":"RECRUITING","sponsor":"Khyber Medical University Peshawar","startDate":"2025-10-01","conditions":"Osteoporosis, Osteoporosis, Postmenopausal","enrollment":40},{"nctId":"NCT05493761","phase":"PHASE4","title":"Effect of Anti-osteoporotic Medications on Nonalcoholic Fatty Liver Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aristotle University Of Thessaloniki","startDate":"2022-12-23","conditions":"Nonalcoholic Fatty Liver, Osteoporosis, Postmenopausal","enrollment":72},{"nctId":"NCT05575167","phase":"","title":"Single or Repeat Zoledronate Versus Alendronate Following Denosumab (EUROpean Denosumab Effects Consolidation Study)","status":"RECRUITING","sponsor":"424 General Military Hospital","startDate":"2023-11-28","conditions":"Osteoporosis, Postmenopausal","enrollment":125},{"nctId":"NCT05151484","phase":"PHASE4","title":"Novel Precision Medicine Approach to Treatment of Osteoporosis Based on Bone Turnover","status":"RECRUITING","sponsor":"Madhumathi Rao","startDate":"2022-03-21","conditions":"Age-Related Osteoporosis","enrollment":60},{"nctId":"NCT04338529","phase":"","title":"Alendronate in an Weekly Effervescent Tablet Formulation Following Denosumab Discontinuation","status":"COMPLETED","sponsor":"251 Hellenic Air Force & VA General Hospital","startDate":"2020-04-01","conditions":"Postmenopausal Osteoporosis","enrollment":92},{"nctId":"NCT00092066","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Efficacy of an Investigational Drug and Dietary Supplement in Men and Postmenopausal Women With Osteoporosis (0217A-227)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-09-24","conditions":"Osteoporosis, Vitamin D Deficiency","enrollment":717},{"nctId":"NCT00092014","phase":"PHASE3","title":"A Study to Evaluate and Compare Alendronate and Risedronate on Bone Mineral Density in Women With Postmenopausal Osteoporosis (MK-0217-211)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-09-01","conditions":"Postmenopausal Osteoporosis","enrollment":1053},{"nctId":"NCT01350934","phase":"PHASE4","title":"A Study to Evaluate Alendronate Sodium /Vitamin D3 Combination Tablets(FOSAMAX PLUS) Versus Calcitriol in the Treatment of Osteoporosis in Postmenopausal Women in China (MK-0217A-264)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2011-06-19","conditions":"Osteoporosis, Postmenopausal","enrollment":219},{"nctId":"NCT00692913","phase":"PHASE3","title":"A Study to Test the Effect of MK0217A on Vitamin D Inadequacy in Postmenopausal Women With Osteoporosis (0217A-262)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2008-06","conditions":"Osteoporosis","enrollment":515},{"nctId":"NCT00729651","phase":"PHASE4","title":"Efficacy and Safety Study of Fosamax Plus D in Postmenopausal Women With Osteoporosis (0217A-263)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2008-03-20","conditions":"Osteoporosis Postmenopausal","enrollment":343},{"nctId":"NCT01437111","phase":"PHASE3","title":"Study of MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet (MK-0217A-329)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2011-10-26","conditions":"Osteoporosis","enrollment":200},{"nctId":"NCT02944799","phase":"PHASE2","title":"Alendronate Treatment of Osteoporosis in Rheumatoid Arthritis","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2015-12","conditions":"Rheumatoid Arthritis, Osteoporosis","enrollment":69},{"nctId":"NCT04555317","phase":"NA","title":"Bone Toxicity Following Pelvic Radiotherapy","status":"UNKNOWN","sponsor":"The Christie NHS Foundation Trust","startDate":"2021-05-17","conditions":"Gynecologic Cancer, Radiotherapy Side Effect, Fracture","enrollment":80},{"nctId":"NCT00580047","phase":"NA","title":"Effects of Zoledronic Acid Versus Alendronate on Bone Loss After Kidney and Kidney/Pancreas Transplants","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2003-12-01","conditions":"Renal Insufficiency","enrollment":59},{"nctId":"NCT02195895","phase":"PHASE2","title":"Effect of Alendronate on Bone in People With Chronic Spinal Cord Injury (SCI) Previously Treated With Teriparatide","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2014-04","conditions":"Spinal Cord Injury, Bone Loss, Osteoporosis","enrollment":17},{"nctId":"NCT01875458","phase":"","title":"Biomarker Identification in Orthopaedic & Oral Maxillofacial Surgery Subjects to Identify Risks of Bisphosphonate Use","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2012-04-13","conditions":"Osteoporosis, With or Without Treatment, Bisphosphonate Treatment, Atypical Femur Fracture","enrollment":314},{"nctId":"NCT02322099","phase":"PHASE4","title":"Alendronate for Prevention of AntiRetroviral Therapy-associated Bone Loss","status":"TERMINATED","sponsor":"University College Dublin","startDate":"2016-05","conditions":"Bone Demineralization","enrollment":53},{"nctId":"NCT00806416","phase":"PHASE1","title":"A Study of the Bioequivalence of 70 mg Alendronate and 70 mg Alendronate in Combination With 2800 IU Vitamin D","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-05","conditions":"Osteoporosis","enrollment":244},{"nctId":"NCT01065779","phase":"","title":"FOSAMAX PLUS and FOSAMAX PLUS D Re-examination Study (0217A-267)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-03","conditions":"Osteoporosis","enrollment":880},{"nctId":"NCT00803790","phase":"PHASE1","title":"A Study of the Bioequivalence of 70-mg Alendronate and 70-mg Alendronate in Combination With 5600 IU Vitamin D (MK0217A-253)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-05","conditions":"Osteoporosis","enrollment":318},{"nctId":"NCT00641771","phase":"PHASE1","title":"4-Week Study to Assess the Effect of Alendronate and Vitamin D3 Once Weekly on Fractional Calcium Absorption in Postmenopausal Osteoporotic Women (0217A-230)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-05","conditions":"Osteoporosis","enrollment":56},{"nctId":"NCT04169698","phase":"PHASE2, PHASE3","title":"Alendronate Versus Denosumab in Kidney Transplant Patients","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2019-10-17","conditions":"Osteoporosis, Osteopenia, Renal Transplant Recipient","enrollment":90},{"nctId":"NCT00921557","phase":"PHASE2","title":"Safety and Effectiveness of Alendronate for Bone Mineral Density in HIV-infected Children and Adolescents","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2009-11","conditions":"HIV Infection","enrollment":52},{"nctId":"NCT02371252","phase":"PHASE4","title":"Efficacy and Safety of Brand Versus Generic Alendronate for Osteoporosis Treatment","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2014-04","conditions":"Osteoporosis","enrollment":140},{"nctId":"NCT04719572","phase":"NA","title":"Intervention Study of Drugs in Patients Osteopenia and Osteoporosis","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2021-03","conditions":"Osteoporosis, Osteopenia, Osteoporosis","enrollment":180},{"nctId":"NCT00354302","phase":"PHASE3","title":"Bone Mineral Density in Postmenopausal Women With Primary Breast Cancer Who Are Receiving Treatment on Clinical Trial","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"2006-04-24","conditions":"Breast Cancer, Osteoporosis","enrollment":497},{"nctId":"NCT00421343","phase":"PHASE3","title":"Secondary Prevention of Osteoporosis","status":"COMPLETED","sponsor":"Hebrew SeniorLife","startDate":"2007-02","conditions":"Osteoporosis","enrollment":29},{"nctId":"NCT00145977","phase":"NA","title":"Texture Analysis for Postmenopausal Osteoporosis","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2001-07","conditions":"Osteoporosis, Osteopenia","enrollment":36},{"nctId":"NCT00885170","phase":"PHASE2","title":"A Study to Evaluate the Safety, Tolerability, and Efficacy of Odanacatib (MK-0822) in Postmenopausal Women Previously Treated With a Bisphosphonate (MK-0822-042)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-04-13","conditions":"Osteoporosis","enrollment":246},{"nctId":"NCT01968850","phase":"PHASE2","title":"Bone Antiresorptive Therapy With Antiretroviral Initiation (BATARI) Pilot Trial","status":"COMPLETED","sponsor":"Unity Health Toronto","startDate":"2014-04-23","conditions":"HIV","enrollment":30},{"nctId":"NCT01882400","phase":"PHASE4","title":"Assessment of Response to Treatment of Osteoporosis With Oral Bisphosphonates in Patients With Muscular Dystrophy","status":"COMPLETED","sponsor":"Gilles Boire","startDate":"2001-05","conditions":"Osteoporosis, Muscular Dystrophy, Cystic Fibrosis","enrollment":11},{"nctId":"NCT00471237","phase":"PHASE2","title":"A Phase II Study Evaluating SB-751689 in Post-Menopausal Women With Osteoporosis.","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2007-05-14","conditions":"Osteoporosis","enrollment":564},{"nctId":"NCT00668941","phase":"PHASE2","title":"Cyclic Versus Daily Teriparatide on Bone Mass","status":"UNKNOWN","sponsor":"Helen Hayes Hospital","startDate":"2005-09","conditions":"Osteoporosis","enrollment":140},{"nctId":"NCT00996801","phase":"PHASE2","title":"MK-5442 in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With an Oral Bisphosphonate (MK-5442-012)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-11","conditions":"Osteoporosis, Postmenopausal Osteoporosis","enrollment":526},{"nctId":"NCT01552122","phase":"PHASE3","title":"Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Alendronate (MK-0822-050)","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-05","conditions":"Osteoporosis, Postmenopausal Osteoporosis","enrollment":""},{"nctId":"NCT01265615","phase":"PHASE4","title":"Paricalcitol Versus Calcitriol for the Management of Renocardiac Syndrome in Renal Transplant Patients","status":"COMPLETED","sponsor":"Ural State Medical University","startDate":"2009-10","conditions":"Cardiorenal Syndrome, Chronic Allograft Nephropathy","enrollment":109},{"nctId":"NCT02416271","phase":"PHASE4","title":"The Forteo Alendronate Comparator Trial","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2001-04","conditions":"Osteoporosis","enrollment":203},{"nctId":"NCT00004488","phase":"PHASE2","title":"Phase II Randomized Study of Alendronate Sodium for Osteopenia in Patients With Gaucher's Disease","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"1998-10","conditions":"Gaucher's Disease, Osteopenia","enrollment":82},{"nctId":"NCT00004489","phase":"NA","title":"Randomized Study of Alendronate in Adult Patients With Cystic Fibrosis Related Osteoporosis","status":"COMPLETED","sponsor":"University of North Carolina","startDate":"1998-10","conditions":"Osteoporosis, Cystic Fibrosis","enrollment":60},{"nctId":"NCT00680953","phase":"PHASE3","title":"Denosumab Fracture Intervention Randomized Placebo Controlled Trial in Japanese Patients With Osteoporosis","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2008-05","conditions":"Osteoporosis","enrollment":1262},{"nctId":"NCT00092079","phase":"PHASE3","title":"A Study of MK0217A and Dietary Supplement in Men and Postmenopausal Women With Osteoporosis (0217A-227)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-01","conditions":"Osteoporosis, Vitamin D Deficiency","enrollment":652},{"nctId":"NCT00460057","phase":"PHASE4","title":"The Change of Bone Markers After Low Dose Alendronate in Postmenopausal Women With Bone Loss","status":"COMPLETED","sponsor":"Eulji University Hospital","startDate":"2006-03","conditions":"Osteoporosis","enrollment":63},{"nctId":"NCT00463268","phase":"PHASE3","title":"Osteoporosis Prevention With Low Dose Alendronate","status":"COMPLETED","sponsor":"University Hospital of Mont-Godinne","startDate":"2007-09","conditions":"Osteopenia","enrollment":83},{"nctId":"NCT00404820","phase":"PHASE3","title":"Safety/Efficacy of Zoledronic Acid and Alendronate on Bone Metabolism in Postmenopausal Women With Osteoporosis","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-10","conditions":"Osteoporosis","enrollment":604},{"nctId":"NCT00593580","phase":"PHASE2","title":"Bone Health in Gynecologic Cancers-does FOSAVANCE Help?","status":"COMPLETED","sponsor":"British Columbia Cancer Agency","startDate":"2008-02","conditions":"Ovarian Cancer","enrollment":60},{"nctId":"NCT00259857","phase":"PHASE2","title":"Safety and Efficacy of Alendronate (Fosamax) in Children With Osteoporosis","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2003-10","conditions":"Osteoporosis","enrollment":22},{"nctId":"NCT00061256","phase":"PHASE2","title":"The Effect of Alendronate, Calcium, and Vitamin D on Bone Mineral Density in HIV Infected Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":80},{"nctId":"NCT00727493","phase":"PHASE4","title":"Osteoporosis and Dental Implant","status":"UNKNOWN","sponsor":"Charite University, Berlin, Germany","startDate":"2004-01","conditions":"Osteoporosis","enrollment":45},{"nctId":"NCT00168909","phase":"PHASE4","title":"Influence of Alfacalcidol on Falls in Osteopenic/Osteoporotic Postmenopausal Women (ALFA Study)","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2003-06","conditions":"Osteoporosis, Postmenopausal, Osteopenia, Falls","enrollment":282},{"nctId":"NCT00138983","phase":"PHASE3","title":"Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol.","status":"COMPLETED","sponsor":"UMC Utrecht","startDate":"2000-05","conditions":"Rheumatoid Arthritis, Polymyalgia Rheumatica, Giant Cell Arteritis","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[{"date":"20070426","type":"SUPPL","sponsor":"ORGANON LLC","applicationNumber":"NDA021762"},{"date":"20100301","type":"SUPPL","sponsor":"ORGANON LLC","applicationNumber":"NDA021762"},{"date":"20061228","type":"SUPPL","sponsor":"ORGANON LLC","applicationNumber":"NDA021762"},{"date":"20260203","type":"SUPPL","sponsor":"ORGANON LLC","applicationNumber":"NDA021762"},{"date":"20150710","type":"SUPPL","sponsor":"ORGANON LLC","applicationNumber":"NDA021762"},{"date":"20130419","type":"SUPPL","sponsor":"ORGANON LLC","applicationNumber":"NDA021762"},{"date":"20100301","type":"SUPPL","sponsor":"ORGANON LLC","applicationNumber":"NDA021762"},{"date":"20110701","type":"SUPPL","sponsor":"ORGANON LLC","applicationNumber":"NDA021762"},{"date":"20151130","type":"SUPPL","sponsor":"ORGANON LLC","applicationNumber":"NDA021762"},{"date":"20110125","type":"SUPPL","sponsor":"ORGANON LLC","applicationNumber":"NDA021762"},{"date":"20100301","type":"SUPPL","sponsor":"ORGANON LLC","applicationNumber":"NDA021762"},{"date":"20050407","type":"ORIG","sponsor":"ORGANON LLC","applicationNumber":"NDA021762"},{"date":"20061228","type":"SUPPL","sponsor":"ORGANON LLC","applicationNumber":"NDA021762"},{"date":"20051102","type":"SUPPL","sponsor":"ORGANON LLC","applicationNumber":"NDA021762"},{"date":"20131107","type":"SUPPL","sponsor":"ORGANON LLC","applicationNumber":"NDA021762"},{"date":"20190816","type":"SUPPL","sponsor":"ORGANON LLC","applicationNumber":"NDA021762"},{"date":"20150408","type":"SUPPL","sponsor":"ORGANON LLC","applicationNumber":"NDA021762"},{"date":"20081008","type":"SUPPL","sponsor":"ORGANON LLC","applicationNumber":"NDA021762"}],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"FOSAMAX PLUS D","genericName":"FOSAMAX PLUS D","companyName":"Organon and Co","companyId":"organon-and-co","modality":"Small molecule","firstApprovalDate":"","aiSummary":"FOSAMAX PLUS D combines alendronate (a bisphosphonate that inhibits bone resorption) with cholecalciferol (vitamin D3) to prevent and treat osteoporosis while ensuring adequate vitamin D status. Used for Osteoporosis prevention and treatment in postmenopausal women, Osteoporosis in men, Glucocorticoid-induced osteoporosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}